Business Wire

PA-IDEMIA/UNISYS

3.6.2020 12:50:07 CEST | Business Wire | Press release

Share
Australian Department of Home Affairs’ New Biometric System Goes Live Using Unisys Stealth(identity)™ and IDEMIA Biometrics

Unisys Corporation (NYSE: UIS) and IDEMIA today announced that the Australian Department of Home Affairs’ new Enterprise Biometric Identification Services (EBIS) system has gone live. EBIS is based on the Unisys Stealth(identity)™ multi-factor identity management and authentication solution and, using IDEMIA’s facial and fingerprint recognition algorithms, is one of the world’s most accurate biometric identity management systems used for visa and border processing to secure Australia’s’ borders and facilitate the flow of legitimate travellers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005403/en/

EBIS will be used by the department to match the facial images and fingerprints of people including those wishing to travel to Australia such as visa applicants and the facial images for citizenship applicants. The system simultaneously facilitates the processing of legitimate travellers and is designed to support anticipated growth in visa applications, border clearances and applications for citizenship over the next 10 years.

In 2019 there was a record annual 9.5 million visitors to Australia, 3.9 million more than 10 years earlier and 220 300 more than the previous year1 . To facilitate travellers’ journeys, border clearance staff need to efficiently verify the identities of travellers and confirm they are who they say they are to prevent delays, avoid queues and improve the overall experience for travellers. In the future, EBIS will provide the capability to quickly flag people who may be crossing the border with fraudulent identities.

Unisys designed and implemented the system within 18 months of signing the contract with the department. EBIS is based on the Stealth(identity) multi-factor identity management and authentication solution, which supports face, finger, iris and voice recognition. It is a robust solution designed for high-volume (more than 100,000 transactions daily) and large-scale galleries (more than 100 million records). Stealth(identity) provides the core biometric identity management functionality of EBIS including the user interface, workflows, business rules, identity data and record linking and auditing functionality. EBIS replaces the previous biometrics matching system that was also provided and supported by Unisys for the last 12 years.

Rick Mayhew, vice president and general manager, Unisys Asia Pacific said: “The long term growth in the volume of travellers that will hopefully return after COVID-19, as well as the increased risk of potential terrorist or fraudulent activity, means that effective border security is more important than ever. EBIS provides Home Affairs with greater confidence in verifying an individual’s identity for efficient and early detection of criminals and persons of national security concern who change names and obtain passports using false identities. We have worked closely with the department and our partner IDEMIA, the global leader in Augmented Identity, to deliver one of the world’s leading solutions to help protect Australia’s borders and national assets.”

The core of EBIS’ fingerprint and facial biometric matching solution uses industry-leading biometric matching algorithms from IDEMIA to quickly and accurately match fingerprints and facial images.

IDEMIA’s flagship product Multi Biometric Search Services (MBSS) is a multi-biometric engine that uses face and fingerprint matching algorithms. This product combines high scalability (over 1 billion identities possible) with high availability, which is necessary for mission-critical systems, integrated within IDEMIA’s world-leading biometric algorithms. The product can also include other modalities such as iris recognition, where required.

Tim Ferris, President of IDEMIA Asia Pacific and Senior Vice President for Public Security and Identity, added: “We are thrilled to provide the biometric engine that powers the EBIS solution. This is the continuation of years of IDEMIA’s engagement in the Australian Borders ecosystem. The combined strengths of IDEMIA behind Unisys provide the Department of Home Affairs with a flagship platform to secure the border now and into the future.”

Unisys has extensive experience supporting government departments and agencies in Australia and around the world. More than 240 government agencies worldwide use Unisys solutions. For more information on Unisys' Public Sector solutions, visit http://www.unisys.com.au/industries/government/public-sector .

1 – Australian Bureau of Statistics -
https://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/3401.0Main%20Features13Mar%202020

About Unisys
Unisys is a global information technology company that builds high-performance, security-centric solutions for the most demanding businesses and governments. Unisys offerings include security software and services; digital transformation and workplace services; industry applications and services; and innovative software operating environments for high-intensity enterprise computing. For more information on how Unisys builds better outcomes securely for its clients across the Government, Financial Services and Commercial markets, visit www.unisys.com.au . Follow Unisys on Twitter and LinkedIn .

###

Unisys and other Unisys products and services mentioned herein, as well as their respective logos, are trademarks or registered trademarks of Unisys Corporation. Any other brand or product referenced herein is acknowledged to be a trademark or registered trademark of its respective holder.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye